QLT Appoints Geoffrey Cox As Interim CEO

(RTTNews) - QLT Inc. (QLTI, QLT.TO) announced that current QLT Board member, Geoffrey Cox, has been appointed interim Chief Executive Officer, effective immediately.

Cox has more than 35 years of business and scientific leadership in the pharmaceutical and biotechnology industries, 13 years of which have been as Chairman and CEO of public companies. Cox will continue in his role as a member of the QLT Board of Directors. In conjunction with Cox's appointment, the QLT Board has disbanded its Executive Transition Committee.

Most recently, Cox served as an independent consultant to the life sciences industry. From 2001 to 2010, Cox was Chairman, President and CEO of GTC Biotherapeutics Inc. (now rEVO Biologics), and from 1997 to 2001 he was Chairman, President and CEO of Aronex Pharmaceuticals Inc. Prior to that, he served at Genzyme Corporation Inc., last serving as its Executive Vice President, Operations. Cox is a former Chairman of MassBio, the Massachusetts Biotechnology Council, and served for a number of years on the Board of the Biotechnology Industries Association.

The company also announced that the 2014 annual general meeting of shareholders will be held in Vancouver, British Columbia, Canada, on Monday, December 15, 2014.